{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T19:12:34Z","timestamp":1785265954782,"version":"3.55.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40262-025-01504-5","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T18:07:55Z","timestamp":1745345275000},"page":"715-728","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Model-Informed Dose Optimization of Pazopanib in Real-World Patients with Cancer"],"prefix":"10.1007","volume":"64","author":[{"given":"Zhiyuan","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swantje","family":"V\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anyue","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Rieborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"van der Hulle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherijne A. J.","family":"Knibbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3219-253X","authenticated-orcid":false,"given":"Dirk Jan A. R.","family":"Moes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"issue":"6","key":"1504_CR1","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/jjco\/hyy053","volume":"48","author":"S Miyamoto","year":"2018","unstructured":"Miyamoto S, Kakutani S, Sato Y, Hanashi A, Kinoshita Y, Ishikawa A. Drug review: pazopanib. Jpn J Clin Oncol. 2018;48(6):503\u201313.","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"1504_CR2","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.ejca.2012.12.010","volume":"49","author":"CN Sternberg","year":"2013","unstructured":"Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH, Zarba JJ, Gladkov OA, Lee E, Szczylik C, McCann L, Rubin SD, Chen M, Davis ID. A randomised, double-blind phase III study of pazopanib in patients with advanced and\/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer (Oxford, England: 1990). 2013;49(6):1287\u201396.","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"issue":"5","key":"1504_CR3","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/annonc\/mdz056","volume":"30","author":"B Escudier","year":"2019","unstructured":"Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, Gr\u00fcnwald V, Gillessen S, Horwich A. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):706\u201320.","journal-title":"Ann Oncol"},{"issue":"5","key":"1504_CR4","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.eururo.2019.02.011","volume":"75","author":"B Ljungberg","year":"2019","unstructured":"Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fern\u00e1ndez-Pello S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Kuusk T, Lam TB, Marconi L, Merseburger AS, Powles T, Staehler M, Tahbaz R, Volpe A, Bex A. European Association of Urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol. 2019;75(5):799\u2013810.","journal-title":"Eur Urol"},{"issue":"9829","key":"1504_CR5","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WT van der Graaf","year":"2012","unstructured":"van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Sch\u00f6ffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (London, England). 2012;379(9829):1879\u201386.","journal-title":"Lancet (London, England)"},{"issue":"1","key":"1504_CR6","first-page":"53","volume":"4","author":"DT Nguyen","year":"2013","unstructured":"Nguyen DT, Shayahi S. Pazopanib: approval for soft-tissue sarcoma. J Adv Pract Oncol. 2013;4(1):53\u20137.","journal-title":"J Adv Pract Oncol"},{"issue":"10","key":"1504_CR7","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1038\/bjc.2014.503","volume":"111","author":"AB Suttle","year":"2014","unstructured":"Suttle AB, Ball HA, Molimard M, Hutson TE, Carpenter C, Rajagopalan D, Lin Y, Swann S, Amado R, Pandite L. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer. 2014;111(10):1909\u201316.","journal-title":"Br J Cancer"},{"key":"1504_CR8","doi-asserted-by":"crossref","unstructured":"Mueller-Schoell A, Groenland SL, Scherf-Clavel O, van Dyk M, Huisinga W, Michelet R, Jaehde U, Steeghs N, Huitema ADR, Kloft C. Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eur J Clin Pharmacol. 2020.","DOI":"10.1007\/s00228-020-03014-8"},{"issue":"6","key":"1504_CR9","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","volume":"28","author":"CN Sternberg","year":"2010","unstructured":"Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarb\u00e1 JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061\u20138.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1504_CR10","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","volume":"369","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Eng J Med. 2013;369(8):722\u201331.","journal-title":"N Eng J Med"},{"issue":"8","key":"1504_CR11","doi-asserted-by":"publisher","first-page":"6583","DOI":"10.1007\/s00520-022-07088-1","volume":"30","author":"V Gaillard","year":"2022","unstructured":"Gaillard V, Lhuillier A, Bigot C, Pierard L, Trensz P, Burgy M, Schuster C, Malouf G, Fritsch A, Lang H, Tricard T, Borchiellini D, Geoffrois L, Barthelemy P. Impact of the app-based and nurse-led supportive care program AKO@dom on dose intensity of oral-targeted therapies in patients with metastatic renal cell cancer: a multicentric observational retrospective study. Support Care Cancer. 2022;30(8):6583\u201391.","journal-title":"Support Care Cancer"},{"issue":"7_suppl","key":"1504_CR12","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1200\/jco.2011.29.7_suppl.345","volume":"29","author":"Y Lin","year":"2011","unstructured":"Lin Y, Ball HA, Suttle B, Mehmud F, Amado RG, Hutson TE, Pandite LN. Relationship between plasma pazopanib concentration and incidence of adverse events in renal cell carcinoma. J Clin Oncol. 2011;29(7_suppl):345\u2013345.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1504_CR13","doi-asserted-by":"publisher","first-page":"e306","DOI":"10.1016\/j.clgc.2018.12.001","volume":"17","author":"S Noda","year":"2019","unstructured":"Noda S, Yoshida T, Hira D, Murai R, Tomita K, Tsuru T, Kageyama S, Kawauchi A, Ikeda Y, Morita SY, Terada T. Exploratory investigation of target pazopanib concentration range for patients with renal cell carcinoma. Clin Genitourin Cancer. 2019;17(2):e306\u201313.","journal-title":"Clin Genitourin Cancer"},{"key":"1504_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115421","volume":"215","author":"IK Minichmayr","year":"2024","unstructured":"Minichmayr IK, Dreesen E, Centanni M, Wang Z, Hoffert Y, Friberg LE, Wicha SG. Model-informed precision dosing: state of the art and future perspectives. Adv Drug Deliv Rev. 2024;215: 115421.","journal-title":"Adv Drug Deliv Rev"},{"key":"1504_CR15","doi-asserted-by":"crossref","unstructured":"Escudero-Ortiz V, Dom\u00ednguez-Le\u00f1ero V, Catal\u00e1n-Latorre A, Rebollo-Liceaga J, Sureda M. Relevance of therapeutic drug monitoring of tyrosine kinase inhibitors in routine clinical practice: a pilot Study Pharmaceutics [Online], 2022.","DOI":"10.3390\/pharmaceutics14061216"},{"issue":"6","key":"1504_CR16","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s00280-014-2599-1","volume":"74","author":"V Gotta","year":"2014","unstructured":"Gotta V, Widmer N, Decosterd LA, Chalandon Y, Heim D, Gregor M, Benz R, Leoncini-Franscini L, Baerlocher GM, Duchosal MA, Csajka C, Buclin T. Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial. Cancer Chemother Pharmacol. 2014;74(6):1307\u201319.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1504_CR17","first-page":"33","volume":"937","author":"NP van Erp","year":"2013","unstructured":"van Erp NP, de Wit D, Guchelaar HJ, Gelderblom H, Hessing TJ, Hartigh J. A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. J Chromatogr. 2013;937:33\u201343.","journal-title":"J Chromatogr"},{"key":"1504_CR18","unstructured":"SERVICES, U. S. D. O. H. A. H. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50. Accessed 27 Nov 2017."},{"key":"1504_CR19","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, de Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, Liu Y, Therasse P, Wolchok JD, Seymour L. RECIST 1.1\u2014Update and clarification: from the RECIST committee. Eur J Cancer (Oxford, England\u202f: 1990). 2016;62:132\u20137.","journal-title":"Eur J Cancer (Oxford, England : 1990)"},{"issue":"3","key":"1504_CR20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40262-016-0443-y","volume":"56","author":"H Yu","year":"2017","unstructured":"Yu H, van Erp N, Bins S, Mathijssen RH, Schellens JH, Beijnen JH, Steeghs N, Huitema AD. Development of a pharmacokinetic model to describe the complex pharmacokinetics of pazopanib in cancer patients. Clin Pharmacokinet. 2017;56(3):293\u2013303.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1504_CR21","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1158\/1078-0432.CCR-18-2748","volume":"25","author":"O Mir","year":"2019","unstructured":"Mir O, Touati N, Lia M, Liti\u00e8re S, Le Cesne A, Sleijfer S, Blay JY, Leahy M, Young R, Mathijssen RHJ, Van Erp NP, Gelderblom H, Van der Graaf WT, Gronchi A. Impact of concomitant administration of gastric acid-suppressive agents and pazopanib on outcomes in soft-tissue sarcoma patients treated within the EORTC 62043\/62072 trials. Clin Cancer Res. 2019;25(5):1479\u201385.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1504_CR22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351.","journal-title":"AAPS J"},{"issue":"8","key":"1504_CR23","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/psp4.12797","volume":"11","author":"RC Van Wijk","year":"2022","unstructured":"Van Wijk RC, Simonsson USH. Finding the right hazard function for time-to-event modeling: a tutorial and shiny application. CPT Pharmacomet Syst Pharmacol. 2022;11(8):991\u20131001.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"1","key":"1504_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10928-015-9454-9","volume":"43","author":"Y Huh","year":"2016","unstructured":"Huh Y, Hutmacher MM. Application of a hazard-based visual predictive check to evaluate parametric hazard models. J Pharmacokinet Pharmacodynam. 2016;43(1):57\u201371.","journal-title":"J Pharmacokinet Pharmacodynam"},{"issue":"10","key":"1504_CR25","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/psp4.12689","volume":"10","author":"F Le Louedec","year":"2021","unstructured":"Le Louedec F, Puisset F, Thomas F, Chatelut \u00c9, White-Koning M. Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open-source R package mapbayr. CPT Pharmacomet Syst Pharmacol. 2021;10(10):1208\u201320.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1504_CR26","doi-asserted-by":"crossref","unstructured":"Ozbey AC, Combarel D, Poinsignon V, Lovera C, Saada E, Mir O, Paci A. Population pharmacokinetic analysis of pazopanib in patients and determination of target AUC. Pharmaceuticals (Basel, Switzerland). 2021;14 (9).","DOI":"10.3390\/ph14090927"},{"issue":"12","key":"1504_CR27","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1158\/1078-0432.CCR-08-2740","volume":"15","author":"HI Hurwitz","year":"2009","unstructured":"Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, Hodge JP, Merkle EM, Pandite L. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res. 2009;15(12):4220\u20137.","journal-title":"Clin Cancer Res"},{"key":"1504_CR28","unstructured":"RESEARCH, C. F. D. E. A., Votrient (pazopanib) tablets. Clin Pharmacol Bipharmaceut Rev. 2009."},{"issue":"8","key":"1504_CR29","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","volume":"369","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. New Eng J Med. 2013;369(8):722\u201331.","journal-title":"New Eng J Med"},{"key":"1504_CR30","unstructured":"Administration, F. a. D., Optimizing the dosage of human prescription drugs and biological products for the treatment of oncologic diseases, guidance for industry. Biologics, U. S. D. o. H. a. H. S. F. a. D. A. O. C. o. E. O. C. f. D. E. a. R. C. C. f., Ed. 2024."},{"key":"1504_CR31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ejca.2019.04.003","volume":"114","author":"AY Shah","year":"2019","unstructured":"Shah AY, Kotecha RR, Lemke EA, Chandramohan A, Chaim JL, Msaouel P, Xiao L, Gao J, Campbell MT, Zurita AJ, Wang J, Corn PG, Jonasch E, Motzer RJ, Sharma P, Voss MH, Tannir NM. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. Eur J Cancer (Oxford, England\u202f: 1990). 2019;114:67\u201375.","journal-title":"Eur J Cancer (Oxford, England : 1990)"},{"issue":"3","key":"1504_CR32","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.clgc.2023.02.007","volume":"21","author":"H Johnston","year":"2023","unstructured":"Johnston H, Deal AM, Morgan KP, Patel B, Milowsky MI, Rose TL. Dose intensity in real-world patients with metastatic renal cell carcinoma taking vascular endothelial growth factor receptor tyrosine kinase inhibitors. Clin Genitourin Cancer. 2023;21(3):357\u201365.","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"1504_CR33","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1080\/14737140.2023.2200168","volume":"23","author":"M Corian\u00f2","year":"2023","unstructured":"Corian\u00f2 M, Giannarelli D, Scartabellati G, De Giorgi U, Brighi N, Fornarini G, Tommasi C, Giudice GC, Rebuzzi SE, Puglisi S, Caffo O, Kinspergher S, Mennitto A, Cattrini C, Santoni M, Verzoni E, Rametta A, Stellato M, Malgeri A, Roviello G, Brunelli M, Signori A, Banna GL, Buti S. Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome? Exp Review Anticancer Ther. 2023;23(5):545\u201354.","journal-title":"Exp Review Anticancer Ther"},{"issue":"5","key":"1504_CR34","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/cpt.1515","volume":"106","author":"FJE Lubberman","year":"2019","unstructured":"Lubberman FJE, Gelderblom H, Hamberg P, Vervenne WL, Mulder SF, Jansman FGA, Colbers A, van der Graaf WTA, Burger DM, Luelmo S, Moes DJAR, van Herpen CML, van Erp NP. The effect of using pazopanib with food vs. fasted on pharmacokinetics, patient safety, and preference (DIET Study). Clin Pharmacol Ther. 2019;106(5):1076\u201382.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"1504_CR35","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Souli\u00e8res D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. New Eng J Med. 2019;380(12):1116\u201327.","journal-title":"New Eng J Med"},{"issue":"3","key":"1504_CR36","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.clinthera.2012.01.014","volume":"34","author":"AM Pick","year":"2012","unstructured":"Pick AM, Nystrom KK. Pazopanib for the treatment of metastatic renal cell carcinoma. Clin Therapeut. 2012;34(3):511\u201320.","journal-title":"Clin Therapeut"},{"issue":"4","key":"1504_CR37","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00280-023-04615-7","volume":"93","author":"K Westerdijk","year":"2024","unstructured":"Westerdijk K, Krens SD, Steeghs N, van der Graaf WTA, Tjwa E, Westdorp H, Desar IME, van Erp NP. Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients. Cancer Chemother Pharmacol. 2024;93(4):353\u201364.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1504_CR38","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/1471-2407-12-311","volume":"12","author":"A Stein","year":"2012","unstructured":"Stein A, Wang W, Carter AA, Chiparus O, Hollaender N, Kim H, Motzer RJ, Sarr C. Dynamic tumor modeling of the dose-response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial. BMC Cancer. 2012;12:311.","journal-title":"BMC Cancer"},{"issue":"4","key":"1504_CR39","first-page":"345","volume":"93","author":"ML Maitland","year":"2013","unstructured":"Maitland ML, Wu K, Sharma MR, Jin Y, Kang SP, Stadler WM, Karrison TG, Ratain MJ, Bies RR. Estimation of renal cell carcinoma treatment effects from disease progression modeling. Cancer Pharmacol Ther. 2013;93(4):345\u201351.","journal-title":"Cancer Pharmacol Ther"},{"issue":"3","key":"1504_CR40","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00280-015-2820-x","volume":"76","author":"L Claret","year":"2015","unstructured":"Claret L, Mercier F, Houk BE, Milligan PA, Bruno R. Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients. Cancer Chemother Pharmacol. 2015;76(3):567\u201373.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"1504_CR41","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00280-013-2191-0","volume":"72","author":"PL Bonate","year":"2013","unstructured":"Bonate PL, Suttle AB. Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma. Cancer Chemother Pharmacol. 2013;72(1):231\u201340.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"1504_CR42","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/psp4.12001","volume":"4","author":"A Ouerdani","year":"2015","unstructured":"Ouerdani A, Struemper H, Suttle AB, Ouellet D, Ribba B. Preclinical modeling of tumor growth and angiogenesis inhibition to describe pazopanib clinical effects in renal cell carcinoma. CPT Pharmacomet Syst Pharmacol. 2015;4(11):660\u20138.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1504_CR43","doi-asserted-by":"crossref","unstructured":"Spratt JR., JS, The rates of growth of skeletal sarcomas. Cancer. 1965;18(1): 14-24.","DOI":"10.1002\/1097-0142(196501)18:1<14::AID-CNCR2820180105>3.0.CO;2-T"},{"issue":"4","key":"1504_CR44","first-page":"928","volume":"109","author":"SG Wicha","year":"2021","unstructured":"Wicha SG, M\u00e4rtson AG, Nielsen EI, Koch BCP, Friberg LE, Alffenaar JW, Minichmayr IK. From therapeutic drug monitoring to model-informed precision dosing for antibiotics. Cancer Pharmacol Ther. 2021;109(4):928\u201341.","journal-title":"Cancer Pharmacol Ther"},{"key":"1504_CR45","doi-asserted-by":"crossref","unstructured":"Goutelle S, Guidi, M, Gotta V, Csajka C, Buclin T, Widmer N. From personalized to precision medicine in oncology: a model-based dosing approach to optimize achievement of imatinib target exposure. Pharmaceutics. 2023;15(4).","DOI":"10.3390\/pharmaceutics15041081"},{"issue":"2","key":"1504_CR46","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40262-023-01336-1","volume":"63","author":"M Centanni","year":"2024","unstructured":"Centanni M, van de Velde ME, Uittenboogaard A, Kaspers GJL, Karlsson MO, Friberg LE. Model-informed precision dosing to reduce vincristine-induced peripheral neuropathy in pediatric patients: a pharmacokinetic and pharmacodynamic modeling and simulation analysis. Clin Pharmacokinet. 2024;63(2):197\u2013209.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1504_CR47","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/cpt.1784","volume":"107","author":"RJ Keizer","year":"2020","unstructured":"Keizer RJ, Dvergsten E, Kolacevski A, Black A, Karovic S, Goswami S, Maitland ML. Get Real: Integration of real-world data to improve patient care. Clin Pharmacol Ther. 2020;107(4):722\u20135.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1504_CR48","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/cpt.3510","volume":"117","author":"AC Dibbets","year":"2025","unstructured":"Dibbets AC, Koldeweij C, Osinga EP, Scheepers HCJ, de Wildt SN. Barriers and facilitators for bringing model-informed precision dosing to the patient\u2019s bedside: a systematic review. Clin Pharmacol Ther. 2025;117(3):633\u201345.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1504_CR49","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/cpt.659","volume":"101","author":"AS Darwich","year":"2017","unstructured":"Darwich AS, Ogungbenro K, Vinks AA, Powell JR, Reny J-L, Marsousi N, Daali Y, Fairman D, Cook J, Lesko LJ, McCune JS, Knibbe CAJ, de Wildt SN, Leeder JS, Neely M, Zuppa AF, Vicini P, Aarons L, Johnson TN, Boiani J, Rostami-Hodjegan A. Why has model-informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future. Clin Pharmacol Ther. 2017;101(5):646\u201356.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1504_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102064","volume":"22","author":"JN Henriksen","year":"2024","unstructured":"Henriksen JN, Andersen CU, Fristrup N. Therapeutic drug monitoring for tyrosine kinase inhibitors in metastatic renal cell carcinoma. Clin Genitourin Cancer. 2024;22(3): 102064.","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"1504_CR51","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00228-020-03014-8","volume":"77","author":"A Mueller-Schoell","year":"2021","unstructured":"Mueller-Schoell A, Groenland SL, Scherf-Clavel O, van Dyk M, Huisinga W, Michelet R, Jaehde U, Steeghs N, Huitema ADR, Kloft C. Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eur J Clin Pharmacol. 2021;77(4):441\u201364.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"1504_CR52","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/bcp.14185","volume":"86","author":"K Westerdijk","year":"2020","unstructured":"Westerdijk K, Desar IME, Steeghs N, van der Graaf WTA, van Erp NP. Imatinib, sunitinib and pazopanib: from flat-fixed dosing towards a pharmacokinetically guided personalized dose. Br J Clin Pharmacol. 2020;86(2):258\u201373.","journal-title":"Br J Clin Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01504-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01504-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01504-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T12:02:42Z","timestamp":1746792162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01504-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1504"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01504-5","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"assertion":[{"value":"24 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The work of Zhiyuan Tan was supported by the China Scholarship Council (202108310028).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Catherijne A.J. Knibbe and Dirk Jan A.R. Moes are Editorial Board members of Clinical Pharmacokinetics. Catherijne A.J. Knibbe and Dirk Jan A.R. Moes were not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Data are available from the corresponding author upon reasonable request. All the model codes were provided in supplementary materials.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code and Data Availability"}},{"value":"This study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. The protocol was approved by the institutional review board (IRB) at the Scientific Committee of the Department of Medical Oncology, Medical Ethics Review Committee Leiden\/Den Haag\/Delft. As retrospective data from routine clinical care were used, a waiver was granted for the requirement of informed consent by the IRB.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"As retrospective data from routine clinical care were used, a waiver was granted for the requirement of informed consent by the IRB.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate\/Consent for Publication"}},{"value":"Z.T., S.V., A.Y., C.A.J.K., and D.J.A.R.M. contributed to the research design, performed research, analyzed data, and wrote the manuscript. A.R., A.J.G., and T.H. treated patients and reviewed and revised the manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}